Ozempic will disrupt big tobacco, candy companies, and alcohol brands
GLP‑1 drugs like Ozempic are being hailed as potentially transformative for obesity and addiction, with users reporting sharply reduced cravings for food, alcohol and other rewards. Commenters weigh this promise against concerns over long‑term safety, side effects, and the ethics of relying on lifelong medication instead of addressing junk food, sedentary lifestyles, and marketing practices. The conversation also highlights steep U.S. pricing, patent and regulatory barriers, and how such drugs could reshape industries from processed food and alcohol to healthcare and pharma R&D incentives.
Scope of Ozempic/GLP‑1 Effects
- Many see GLP‑1 agonists (Ozempic, Wegovy, Mounjaro, etc.) as the most effective and safest weight‑loss drugs yet, with strong appetite/craving reduction and possible addiction benefits.
- Some anecdotal reports: food becomes less salient (“food noise” down), smaller portions, less interest in high‑reward foods; others still want treats but in reduced amounts.
- There is speculation they could reduce consumption of junk food, alcohol, tobacco, and even gambling, with big implications for those industries.
Long‑Term Use, “Lifestyle” vs. Medication
- One camp: obesity is largely behavioral/environmental; drugs should be a temporary “reset” while people fix diet and exercise.
- Another camp: for most obese people, behavior programs fail at scale; GLP‑1s will function like statins or insulin—lifelong treatments that are still “miles better than the alternative.”
- Some worry about a dystopian reliance on drugs to compensate for unhealthy environments; others frame that as rational “body‑hacking” for a modern world our biology isn’t adapted to.
Efficacy, Relapse, and Alternatives
- Claims that most people regain much of the weight after stopping; others counter that rebound is partial (e.g., ~5% net loss) and still worthwhile.
- Strong disagreement about how often obesity or type 2 diabetes can be reversed “naturally” via low‑carb, fasting, or ketogenic diets; thread cites papers both for and against broad generalization.
- GLP‑1s are contrasted with surgery, stimulants (Adderall/meth), and behavioral programs.
Safety and Side Effects
- GLP‑1 agonists have been in use since mid‑2000s, but very long‑term effects (multi‑decade, brain/reward‑system impacts, cancer risk) are seen as uncertain.
- Known or reported side effects: GI issues (constipation/diarrhea/bloating), occasional acid reflux, possible sleep issues, and one report of low libido/ED.
- Several argue that, given the high health risk of obesity/addiction, GLP‑1 risks are likely the lesser evil, but this is not definitively settled.
Price, Access, and Pharma Incentives
- US price (
$1,000/month) vs. very low estimated manufacturing cost ($5/month) is heavily criticized. - Discussion of patents, “evergreening,” dosage/formulation strategies, and compounding pharmacies; some see emerging competition (other GLP‑1s, oral forms, India/China generics) as eventual price relief.
- Debate over price controls vs. market incentives, and whether current systems push pharma toward chronic treatments over one‑shot cures.